Member Info for Toukankahmoon

Doggy

I don’t think any of us understand it.

Even though I have warned caution in the past, my main point was that it would take longer and the SP would not reach the dizzy heights ramped on here.

But I did not expect this. This surpasses the LFT shafting.

If arm 2 delivers the data then they may still get a good license deal. Fingers crossed

We would have to be mad to do a placing at this SP

Be suicide to do a placing now especially as we don’t need more funds yet

Bella

Or it could point to “nothing to present”☹️

John

I to you were giving yourself until the end of the week even though you can’t say why other than the SP making some sort of pattern

Icecool

TBH I believe AVA6000 has shown enough already to be a marked improvement on dox even if with current dosing regime it is just stopping disease progression . But I believe to be the success we all want and expect it to be it needs to show consistent tumour reduction across most if not all patients. I am expecting arm 2 data to show this unequivocally. Until then, in Dr Tap’s own words “ . . . encouraging. . potentially . . . encouraging “.

I clearly state that;

The platform works

AVA6000 is being cleaved predominantly at the tumour

I’m not sure about rate of cleaving fix versus excretion of AVA6000 from the body

One patient with a 65% reduction in tumour is amazing but not statistically significant

Ditto the small number of biopsies out of the total number of patients

Gen

Confess I haven’t been watching the Diagnostics side.

It would be brilliant if that came to pass👍

Oh and just to improve my popularity

Yes the platform works.

Yes AVA6000 is being cleaved

But I’m still not sure enough is being cleaved at the tumour before the bulk is excreted from the system. Hence 2 weekly doing INHO

Icecool

I’ve said when I expect the ongoing discussions to conclude and that is mid year. And most certainly they will have to be well underway now and no doubt are anticipating great arm 2 data.

Gen

Good point and it will help the balance sheet but I doubt the SP would reach the heights we need it to on that alone.

The likelihood is that the SP will continue to slide until arm 2 data published around mid year with perhaps a brief spike when C7 data released. Because there are signs of improvement elsewhere and folks can use their cash to invest in other companies and make money in the meantime. So why keep it in Avacta doing nothing.

And no amount of scaremongering by the cheerleaders that there is going to be a pivotal RNS tomorrow will change that.

More fantastic rumours

Watching

None of the trolls wish you harm. Why is it you are such a bitter and angry chap that you constantly want harm to come to us?

Icecool

I agree that most proble is a licence deal but not until incontrovertible data is published from arm 2 after mid year

Please tell me that the cheerleaders aren’t going to keep up this fantasising about c7 data or a takeover or a joint venture next week all the way through until mid year when we get arm 2 data and all is revealed.

Watching

A joint venture with whom?

Where did you get this info?

Strangy

Don’t you read any of the stuff that comes out of Avacta?

News is not imminent

Anyone know if Myles had his audience with Alastair today after we all fed him such excellent questions or is there a new date mooted for this?